LEADER 05720nam 22006855 450 001 9910300358503321 005 20200630165154.0 010 $a3-319-08046-6 024 7 $a10.1007/978-3-319-08046-8 035 $a(CKB)3710000000227174 035 $a(EBL)1802555 035 $a(SSID)ssj0001338736 035 $a(PQKBManifestationID)11704398 035 $a(PQKBTitleCode)TC0001338736 035 $a(PQKBWorkID)11338302 035 $a(PQKB)10323799 035 $a(MiAaPQ)EBC1802555 035 $a(DE-He213)978-3-319-08046-8 035 $a(PPN)18062251X 035 $a(EXLCZ)993710000000227174 100 $a20140827d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aInflammation in Parkinson's Disease $eScientific and Clinical Aspects /$fedited by Madhavi Thomas 205 $a1st ed. 2014. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2014. 215 $a1 online resource (236 p.) 300 $aDescription based upon print version of record. 311 $a1-322-13716-1 311 $a3-319-08045-8 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aDedication; Foreword; Preface; Contents; Contributors; Parkinson's Disease: An Overview of Etiology, Clinical Manifestations, and Treatment; Clinical Features; Laboratory Studies; Etiology of PD; Selective Vulnerability of the Nigrostriatal Tract; Environmental Factors; Genetic Factors; ?-Synuclein; Parkin; PINK1; DJ-1; LRRK2; UCH-L1; Gene-Environment Interactions; Infectious Etiologies for PD; PD as a Prion-Like Disease; Inflammation and PD; Oxidative Stress and PD; Mechanism of Action of PD Medications; Levodopa; Dopamine Agonists; MAO Inhibitors; COMT Inhibitors 327 $aAnticholinergics and Amantadine Management of Motor Fluctuations and Dyskinesia; Management of Cognitive and Psychiatric Symptoms; Treatment of Nonmotor Symptoms; Neuroprotective Strategies; Surgical Treatment of Parkinson's Disease; References; Neuropathology of Parkinson's Disease; Introduction; Basic Neuropathology of PD; Degeneration of the Nigrostriatal System; Neuronal Vulnerability; Multiorgan Distribution of ?-Synuclein and Lewy Pathologies; Development of ?-Synuclein/Lewy Pathology; Structure and Molecular Components of Lewy Bodies; Pathobiological Role of Lewy Bodies 327 $aLewy Pathology Staging Incidental Lewy Body Disease; New Guidelines for Lewy Pathology; Interaction Between ?-Syn and Other Proteins; Pathophysiology of Clinical Subtypes of Parkinson's Disease; Neuropathology of Cognitive Changes in Parkinson's Disease; Mild Cognitive Impairment in Parkinson's Disease; Parkinson's Disease and Dementia (PDD); Dementia with Lewy Bodies and Parkinson's Disease Dementia; Etiology and Pathogenesis of PD; Animal Models of Parkinson's Disease; Conclusion and Future Directions; References 327 $aRole of the Innate and Adaptive Immune System in the Pathogenesis of PDIntroduction; Immune-Relevant Parkinson's Disease Pathology; Potential Inflammatory Etiology of Sporadic Parkinson's Disease; Evidence for Inflammation in PD; Microglial Activation and MHC in PD; T Lymphocytes in PD; Antibodies and B Lymphocytes in PD; Genetic Mutations that Cause PD and Adaptive Immunity; Immunomodulatory Therapies; Conclusion; References; "Good" and "Bad" Microglia in Parkinson's Disease: An Understanding of Homeostatic Mechanisms in Immunomodulation; Parkinson's Disease and Neuroinflammation 327 $aMicroglia Involvement in PD Pathogenesis "Good" Microglia and "Bad" Microglia; Regulatory Mechanisms of "Good" and "Bad" Microglia; Inducers and Effectors of "Bad" Microglia; Inducers of "Bad" Microglia; ?-Synuclein Aggregates; Environmental Factors; LPS; MPTP; Effectors of "Bad" Microglia; NADPH Oxidase; Pro-inflammatory Factors; ROS and Superoxide; Regulation of "Good" Microglia; Counter-Regulation or Transrepression Pathways; Glucocorticoid Receptors; Estrogen Receptors; NR4A2; Peroxisome Proliferator-Activated Receptors; Anti-inflammatory Factors 327 $aNeuron-Microglia Cross-Talk 330 $aInflammation in Parkinson?s Disease brings advances in research together with current literature and evidence.  This concise volume covers the fundamentals of neuroimmunology and inflammatory models, the interactions between pathways of neurodegeneration and follows the concept of research work undertaken from basic science to clinical trials.  Researchers, clinicians, and students interested in Parkinson's Disease are provided with a comprehensive view of translational research methods and an insight needed for developing future therapies aimed at disease modulation.  . 606 $aNeurology  606 $aInternal medicine 606 $aMedical biochemistry 606 $aNeurology$3https://scigraph.springernature.com/ontologies/product-market-codes/H36001 606 $aInternal Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H33002 606 $aMedical Biochemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/H35005 615 0$aNeurology . 615 0$aInternal medicine. 615 0$aMedical biochemistry. 615 14$aNeurology. 615 24$aInternal Medicine. 615 24$aMedical Biochemistry. 676 $a612.015 676 $a616.8/33 702 $aThomas$b Madhavi$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910300358503321 996 $aInflammation in Parkinson's Disease$91521782 997 $aUNINA